{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:56:29Z","timestamp":1790596589143,"version":"4.1.0"},"reference-count":169,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2732821","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:09:13Z","timestamp":1790593753000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Molecular insights into triazole-based compounds for triple-negative breast cancer treatment"],"prefix":"10.1080","volume":"41","author":[{"given":"Ahamed","family":"Vilangalil","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Yenepoya Pharmacy College & Research Center, Yenepoya (Deemed to be University)","place":["Mangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu Priya","family":"E. S.","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Yenepoya Pharmacy College & Research Center, Yenepoya (Deemed to be University)","place":["Mangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-2953","authenticated-orcid":false,"given":"Sarad Pawar Naik","family":"Bukke","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Department of Pharmacy, Victoria University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"V.","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Yenepoya Pharmacy College & Research Center, Yenepoya (Deemed to be University)","place":["Mangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Meha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Yenepoya Pharmacy College & Research Center, Yenepoya (Deemed to be University)","place":["Mangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekar","family":"Thalluri","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Science, Assam Down Town University (AdtU)","place":["Guwahati, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasolo","family":"Daniel","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Department of Pharmacy, Victoria University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Amooti","family":"Ahikiriza","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Department of Pharmacy, Victoria University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.681476"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174280"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0095"},{"key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong N","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.","journal-title":"Front Oncol"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28227513"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"e_1_3_5_9_1","unstructured":"Gaule P. c-Met\/HGF in triple negative breast cancer [PhD Thesis]. [accessed 2026\u2009Ma 11]. https:\/\/doras.dcu.ie\/20582\/.2015."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241234780"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4516454"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27123661"},{"issue":"1","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12935-024-03313-5","article-title":"Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy","volume":"24","author":"Zhao Y-X","year":"2024","unstructured":"Zhao Y-X, Wang H, Zhang S-W, Zhang W-X, Jiang Y-Z, Shao Z-M. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy. Cancer Cell Int. 2024;24(1):131.","journal-title":"Cancer Cell Int"},{"key":"e_1_3_5_14_1","unstructured":"Shrestha M. Targeting vulnerabilities in RB-deficient breast cancer [PhD Thesis]. University of Toronto (Canada). [accessed 2026 Mar 11]. https:\/\/search.proquest.com\/openview\/55453b172e2d808c99cbf3283d39b580\/1?pq-origsite=gscholar&cbl=18750&diss=y. 2023."},{"issue":"2","key":"e_1_3_5_15_1","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.soi.2024.100059","article-title":"The neoadjuvant approach to treatment of breast cancer: multidisciplinary management to improve outcomes","volume":"1","author":"Baskin AS","year":"2024","unstructured":"Baskin AS, Huppert LA, Kelil T, Singer L, Mukhtar RA. The neoadjuvant approach to treatment of breast cancer: multidisciplinary management to improve outcomes. Surg Oncol Insight. 2024;1(2):100059.","journal-title":"Surg Oncol Insight"},{"issue":"1","key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oncolo\/oyab003","article-title":"Early-stage triple-negative breast cancer: time to optimize personalized strategies","volume":"27","author":"Abuhadra N","year":"2022","unstructured":"Abuhadra N, Stecklein S, Sharma P, Moulder S. Early-stage triple-negative breast cancer: time to optimize personalized strategies. Oncologist. 2022;27(1):30\u201339.","journal-title":"Oncologist"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102410"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102140"},{"key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"1495675","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong Y","year":"2024","unstructured":"Tong Y, Fan X, Liu H, Liang T. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions. Front Immunol. 2024;15:1495675.","journal-title":"Front Immunol"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002597"},{"issue":"7","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby S","year":"2021","unstructured":"Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, Tang S, Hamed SS, Song P, Charlab R, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(7):1850\u20131854.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer","volume":"31","author":"Royce M","year":"2025","unstructured":"Royce M, Shah M, Zhang L, Cheng J, Bonner MK, Pegues M, Miller CP, Leu L, Price LSL, Qiu J, et al. FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer. Clin Cancer Res. 2025;31(21):4405\u20134411.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02050"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S575152"},{"key":"e_1_3_5_26_1","first-page":"12","article-title":"Biochemical and molecular mechanisms of action of cisplatin in cancer cells","author":"Petrovi\u0107 M","year":"2016","unstructured":"Petrovi\u0107 M, Todorovi\u0107 D. Biochemical and molecular mechanisms of action of cisplatin in cancer cells. Facta Univ Ser Med Biol. 2016;18(1):12\u201318.","journal-title":"Facta Univ Ser Med Biol"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr4004049"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(97)90020-5"},{"issue":"1","key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41523-023-00541-2","article-title":"A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st\/2nd line metastatic triple-negative breast cancer","volume":"9","author":"Page DB","year":"2023","unstructured":"Page DB, Pucilowska J, Chun B, Kim I, Sanchez K, Moxon N, Mellinger S, Wu Y, Koguchi Y, Conrad V, et al. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st\/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):53.","journal-title":"NPJ Breast Cancer"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030552"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153739"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.11.029"},{"key":"e_1_3_5_34_1","volume-title":"Potential anticancer activity of novel triazoles and related derivatives","author":"Aguirre-de Paz J","year":"2024","unstructured":"Aguirre-de Paz J, Lara-Almaz\u00e1n N, Ancira-Cortez A, et al. Potential anticancer activity of novel triazoles and related derivatives. Cham: Springer International Publishing; 2024."},{"key":"e_1_3_5_35_1","doi-asserted-by":"crossref","first-page":"100069","DOI":"10.1016\/j.amolm.2025.100069","article-title":"Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: targeting EGFR and CDK4\/6 pathways","volume":"5","author":"Samantaray A","year":"2025","unstructured":"Samantaray A, Pradhan D. Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: targeting EGFR and CDK4\/6 pathways. Asp Mol Med. 2025;5:100069.","journal-title":"Asp Mol Med"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116578"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.140060"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.137803"},{"key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"103919","DOI":"10.1016\/j.etap.2022.103919","article-title":"Triazole fungicide tebuconazole induces apoptosis through ROS-mediated endoplasmic reticulum stress pathway","volume":"94","author":"Othm\u00e8ne YB","year":"2022","unstructured":"Othm\u00e8ne YB, Monceaux K, Belhadef A, et al. Triazole fungicide tebuconazole induces apoptosis through ROS-mediated endoplasmic reticulum stress pathway. Environ Toxicol Pharmacol. 2022;94:103919.","journal-title":"Environ Toxicol Pharmacol"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/ad403e"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c06531"},{"key":"e_1_3_5_43_1","doi-asserted-by":"crossref","first-page":"115858","DOI":"10.1016\/j.ejmech.2023.115858","article-title":"Design, synthesis, and biological evaluation of novel 4, 4\u2032-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer","volume":"261","author":"Gao G","year":"2023","unstructured":"Gao G, Li J, Cao Y, Li X, Qian Y, Wang X, Li M, Qiu Y, Wu T, Wang L, et al. Design, synthesis, and biological evaluation of novel 4, 4\u2032-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. Eur J Med Chem. 2023;261:115858.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00652"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202000170"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.0c04595"},{"key":"e_1_3_5_47_1","doi-asserted-by":"crossref","first-page":"102150","DOI":"10.1016\/j.rechem.2025.102150","article-title":"Development of novel pyrimidine-thio-triazoles targeting EGFR in breast Cancer cells via one-pot copper-catalyzed 1, 3-dipolar cycloaddition","volume":"14","author":"Narasimhachar BC","year":"2025","unstructured":"Narasimhachar BC, Ravish A, Beeraka NM, Pookunoth BC, Basappa S, Vishwanath D, Rangappa KS, Nagaraja O, Madegowda M, Chandrashekara PG, et al. Development of novel pyrimidine-thio-triazoles targeting EGFR in breast Cancer cells via one-pot copper-catalyzed 1, 3-dipolar cycloaddition. Results Chem. 2025;14:102150.","journal-title":"Results Chem"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2253906"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220415225334"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2011.02.001"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986712803414213"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04350-1"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2015.51.12.2421058"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr5003134"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.08.010"},{"key":"e_1_3_5_56_1","first-page":"1","article-title":"Triazoles as enzyme inhibitors: synthetic advances, mechanism of action, molecular docking studies and structure-activity relationships","volume":"4","author":"Hashmi SZ.","year":"2026","unstructured":"Hashmi SZ. Triazoles as enzyme inhibitors: synthetic advances, mechanism of action, molecular docking studies and structure-activity relationships. Mol Divers. 2026;4:1\u201346.","journal-title":"Mol Divers"},{"key":"e_1_3_5_57_1","first-page":"1","article-title":"Triazole-based inhibitors for breast cancer: biological activity, SAR and synthetic strategies","volume":"19","author":"Sharma M","year":"2026","unstructured":"Sharma M, Gandhi A, Sharma K. Triazole-based inhibitors for breast cancer: biological activity, SAR and synthetic strategies. Mol Divers. 2026;19:1\u201347.","journal-title":"Mol Divers"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.2174\/0115680266307132240509065351"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27104172"},{"issue":"7","key":"e_1_3_5_60_1","doi-asserted-by":"crossref","first-page":"e202400637","DOI":"10.1002\/cbdv.202400637","article-title":"Significance of triazole in medicinal chemistry: advancement in drug design, reward and biological activity","volume":"21","author":"Ajmal M","year":"2024","unstructured":"Ajmal M, Mahato AK, Khan M, Rawat S, Husain A, Almalki EB, Alzahrani MA, Haque A, Hakme MJM, Albalawi AS, et al. Significance of triazole in medicinal chemistry: advancement in drug design, reward and biological activity. Chem Biodivers. 2024;21(7):e202400637.","journal-title":"Chem Biodivers"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed10050142"},{"issue":"8","key":"e_1_3_5_62_1","doi-asserted-by":"crossref","first-page":"e2000081","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase inhibitors: role in postmenopausal breast cancer","volume":"353","author":"Kharb R","year":"2020","unstructured":"Kharb R, Haider K, Neha K, Yar MS. Aromatase inhibitors: role in postmenopausal breast cancer. Arch Pharm (Weinheim). 2020;353(8):e2000081.","journal-title":"Arch Pharm (Weinheim)"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5349279"},{"issue":"1","key":"e_1_3_5_64_1","doi-asserted-by":"crossref","first-page":"19664","DOI":"10.1038\/s41598-024-70516-1","article-title":"Ergosterol inhibits the proliferation of breast cancer cells by suppressing AKT\/GSK-3beta\/beta-catenin pathway","volume":"14","author":"Nilkhet S","year":"2024","unstructured":"Nilkhet S, Vongthip W, Lertpatipanpong P, Prasansuklab A, Tencomnao T, Chuchawankul S, Baek SJ. Ergosterol inhibits the proliferation of breast cancer cells by suppressing AKT\/GSK-3beta\/beta-catenin pathway. Sci Rep. 2024;14(1):19664.","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_3_5_65_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1871520616666160811113531","article-title":"Recent advancements in 1, 4-disubstituted 1H-1, 2, 3-triazoles as potential anticancer agents","volume":"18","author":"Lal K","year":"2018","unstructured":"Lal K, Yadav P. Recent advancements in 1, 4-disubstituted 1H-1, 2, 3-triazoles as potential anticancer agents. Anticancer Agents Med Chem. 2018;18(1):21\u201337.","journal-title":"Anticancer Agents Med Chem"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.07.032"},{"issue":"20","key":"e_1_3_5_67_1","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.3390\/molecules28207092","article-title":"New 1, 2, 3-triazole\/1, 2, 4-triazole hybrids as aromatase inhibitors: design, synthesis, and apoptotic antiproliferative activity","volume":"28","author":"Maghraby MT-E","year":"2023","unstructured":"Maghraby MT-E, Mazyad Almutairi T, Br\u00e4se S, Salem OIA, Youssif BGM, Sheha MM. New 1, 2, 3-triazole\/1, 2, 4-triazole hybrids as aromatase inhibitors: design, synthesis, and apoptotic antiproliferative activity. Molecules. 2023;28(20):7092.","journal-title":"Molecules"},{"key":"e_1_3_5_68_1","unstructured":"Mokoena TP. Design and synthesis of quinoline-triazole schiff base metal complexes as potential anti-cancer agents [PhD Thesis]. 2023. [accessed 2026 Mar12]. http:\/\/ul.netd.ac.za\/handle\/10386\/4611."},{"issue":"9","key":"e_1_3_5_69_1","doi-asserted-by":"crossref","first-page":"e202404147","DOI":"10.1002\/slct.202404147","article-title":"Exploring the future of metal-based anticancer agents: a comprehensive review of ruthenium-based complexes","volume":"10","author":"Bhattacharya S","year":"2025","unstructured":"Bhattacharya S, Adon T, Dsouza K, Kumar HY. Exploring the future of metal-based anticancer agents: a comprehensive review of ruthenium-based complexes. ChemistrySelect. 2025;10(9):e202404147.","journal-title":"ChemistrySelect"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2025.2458450"},{"key":"e_1_3_5_71_1","unstructured":"Bagnolini G. Design and synthesis of RAD51-BRCA2 disruptors that trigger synthetic lethality in pancreatic cancer in combination with Olaparib. 2021. [accessed 2026 Apr 10]. https:\/\/amsdottorato.unibo.it\/id\/eprint\/9589\/."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.864286"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/catal11091120"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c04883"},{"issue":"4","key":"e_1_3_5_75_1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1871520615666150819121106","article-title":"Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review","volume":"16","author":"Kaur R","year":"2016","unstructured":"Kaur R, Dwivedi AR, Kumar B, Kumar V. Recent developments on 1, 2, 4-triazole nucleus in anticancer compounds: a review. Anticancer Agents Med Chem. 2016;16(4):465\u2013489.","journal-title":"Anticancer Agents Med Chem"},{"issue":"15","key":"e_1_3_5_76_1","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1021\/acs.organomet.2c00246","article-title":"Copper-catalyzed azide\u2013alkyne cycloaddition (CuAAC) by functionalized NHC-based polynuclear catalysts: scope and mechanistic insights","volume":"41","author":"Gonz\u00e1lez-Lainez M","year":"2022","unstructured":"Gonz\u00e1lez-Lainez M, Gallegos M, Munarriz J, Azpiroz R, Passarelli V, Jim\u00e9nez MV, P\u00e9rez-Torrente JJ. Copper-catalyzed azide\u2013alkyne cycloaddition (CuAAC) by functionalized NHC-based polynuclear catalysts: scope and mechanistic insights. Organometallics. 2022;41(15):2154\u20132169.","journal-title":"Organometallics"},{"key":"e_1_3_5_77_1","doi-asserted-by":"crossref","first-page":"139006","DOI":"10.1016\/j.molstruc.2024.139006","article-title":"Synthesis of 4-(3-(1-substituted\/unsubstituted-phenyl-1H-1, 2, 3-triazole-4-yl) propoxy) benzaldehydes: in vitro antimicrobial, antimalarial activities and In silico docking study","volume":"1317","author":"Al-Salehi MA","year":"2024","unstructured":"Al-Salehi MA, Parmar MP, Rajani DP, Patel HM, Trivedi JH. Synthesis of 4-(3-(1-substituted\/unsubstituted-phenyl-1H-1, 2, 3-triazole-4-yl) propoxy) benzaldehydes: in vitro antimicrobial, antimalarial activities and In silico docking study. J Mol Struct. 2024;1317:139006.","journal-title":"J Mol Struct"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.3c02836"},{"issue":"1","key":"e_1_3_5_79_1","doi-asserted-by":"crossref","first-page":"e202400190","DOI":"10.1002\/tcr.202400190","article-title":"A review on chemistry and methods of synthesis of 1,2,4-triazole derivatives","volume":"25","author":"Couto Rodrigues S","year":"2025","unstructured":"Couto Rodrigues S, Silva Morat\u00f3rio de Moraes R, Tavares de Almeida Pinto G, Miranda Martins MT, Antunes do Nascimento P, Alves Soares DL, Mestre Botelho AB, Cardoso Cruz C, Cunha AC. A review on chemistry and methods of synthesis of 1,2,4-triazole derivatives. Chem Rec. 2025;25(1):e202400190.","journal-title":"Chem Rec"},{"key":"e_1_3_5_80_1","doi-asserted-by":"crossref","first-page":"891484","DOI":"10.3389\/fchem.2022.891484","article-title":"Synthesis methods of 1, 2, 3-\/1, 2, 4-triazoles: a review","volume":"10","author":"Dai J","year":"2022","unstructured":"Dai J, Tian S, Yang X, Liu Z. Synthesis methods of 1, 2, 3-\/1, 2, 4-triazoles: a review. Front Chem. 2022;10:891484.","journal-title":"Front Chem"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1039\/D4RA06886F"},{"key":"e_1_3_5_82_1","first-page":"308","article-title":"Advances in the synthesis of fused 1, 2, 3-triazoles via a MCR-intramolecular azide-alkyne cycloaddition Approach","volume":"28","author":"Thomas J","year":"2023","unstructured":"Thomas J, Dehaen W, John J. Advances in the synthesis of fused 1, 2, 3-triazoles via a MCR-intramolecular azide-alkyne cycloaddition Approach. Molecules. 2023;28:308.","journal-title":"Molecules"},{"key":"e_1_3_5_83_1","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/asia.201100404","article-title":"Metal-Free 1,5-regioselective azide\u2013alkyne [3\u2009+\u20092]-cycloaddition","volume":"6","author":"Kloss F","year":"2011","unstructured":"Kloss F, K\u00f6hn U, Jahn BO, et al. Metal-Free 1,5-regioselective azide\u2013alkyne [3\u2009+\u20092]-cycloaddition. Chem \u2013 Asian J. 2011;6:2816\u20132824.","journal-title":"Chem \u2013 Asian J"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00458K"},{"key":"e_1_3_5_85_1","doi-asserted-by":"crossref","first-page":"115699","DOI":"10.1016\/j.ejmech.2023.115699","article-title":"Current development of 1, 2, 3-triazole derived potential antimalarial scaffolds: structure-activity relationship (SAR) and bioactive compounds","volume":"259","author":"Rahman SMA","year":"2023","unstructured":"Rahman SMA, Bhatti JS, Thareja S, et al. Current development of 1, 2, 3-triazole derived potential antimalarial scaffolds: structure-activity relationship (SAR) and bioactive compounds. Eur J Med Chem. 2023;259:115699.","journal-title":"Eur J Med Chem"},{"issue":"190","key":"e_1_3_5_86_1","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.24976\/Discov.Med.202436190.198","article-title":"Regulating histone deacetylases and carbonic anhydrases by metal complexes: a potent strategy for treating cancers","volume":"36","author":"Nguyen YT","year":"2024","unstructured":"Nguyen YT, Kim N, Lee HJ. Regulating histone deacetylases and carbonic anhydrases by metal complexes: a potent strategy for treating cancers. Discov Med. 2024;36(190):2152\u20132174.","journal-title":"Discov Med"},{"issue":"1","key":"e_1_3_5_87_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof7010001","article-title":"Sterol 14\u03b1-demethylase ligand-binding pocket-mediated acquired and intrinsic azole resistance in fungal pathogens","volume":"7","author":"Rosam K","year":"2020","unstructured":"Rosam K, Monk BC, Lackner M. Sterol 14\u03b1-demethylase ligand-binding pocket-mediated acquired and intrinsic azole resistance in fungal pathogens. JoF. 2020;7(1):1.","journal-title":"JoF"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112652"},{"issue":"11","key":"e_1_3_5_89_1","doi-asserted-by":"crossref","first-page":"e202200679","DOI":"10.1002\/cbdv.202200679","article-title":"Synthetic and medicinal perspective of 1,2,4-triazole as anticancer agents","volume":"19","author":"Rathod B","year":"2022","unstructured":"Rathod B, Kumar K. Synthetic and medicinal perspective of 1,2,4-triazole as anticancer agents. Chem Biodivers. 2022;19(11):e202200679.","journal-title":"Chem Biodivers"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020211"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30030605"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28186536"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.007671"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1550158"},{"issue":"4","key":"e_1_3_5_95_1","doi-asserted-by":"crossref","first-page":"acsbiomedchemau","DOI":"10.1021\/acsbiomedchemau.4c00132","article-title":"Mitigating antimicrobial resistance through strategic design of multimodal antibacterial agents based on 1,2,3-triazole with click chemistry","volume":"5","author":"Chathangad SN","year":"2025","unstructured":"Chathangad SN, Vijayan VN, George JA, Sadhukhan S. Mitigating antimicrobial resistance through strategic design of multimodal antibacterial agents based on 1,2,3-triazole with click chemistry. ACS Bio Med Chem Au. 2025;5(4):acsbiomedchemau.4c00132\u2013504.","journal-title":"ACS Bio Med Chem Au"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.6b00251"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01567-5"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.03.020"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.10190"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.032359"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985363"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008672"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108150"},{"key":"e_1_3_5_104_1","volume-title":"Madame curie bioscience database [Internet]","author":"Duffy AM","year":"2013","unstructured":"Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. In Madame curie bioscience database [Internet]. Austin (TX): Landes Bioscience; 2013 [accessed 2025 May 29]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6482\/."},{"issue":"11","key":"e_1_3_5_105_1","doi-asserted-by":"crossref","first-page":"107867","DOI":"10.1016\/j.jbc.2024.107867","article-title":"Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells","volume":"300","author":"Rotenberg N","year":"2024","unstructured":"Rotenberg N, Feldman M, Shirian J, Hockla A, Radisky ES, Shifman JM. Engineered TIMP2 with narrow MMP-9 specificity is an effective inhibitor of invasion and proliferation of triple-negative breast cancer cells. J Biol Chem. 2024;300(11):107867.","journal-title":"J Biol Chem"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21948"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020169"},{"issue":"9","key":"e_1_3_5_108_1","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1039\/D4MD00285G","article-title":"Development of di-arylated 1, 2, 4-triazole-based derivatives as therapeutic agents against breast cancer: synthesis and biological evaluation","volume":"15","author":"Deb M","year":"2024","unstructured":"Deb M, Singh H, Manhas D, Nandi U, Guru SK, Das P. Development of di-arylated 1, 2, 4-triazole-based derivatives as therapeutic agents against breast cancer: synthesis and biological evaluation. RSC Med Chem. 2024;15(9):3097\u20133113.","journal-title":"RSC Med Chem"},{"issue":"1","key":"e_1_3_5_109_1","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1038\/s41598-026-41032-1","article-title":"New indole-linked 1, 2, 4-triazole derivatives as dual FAK inhibitors and apoptosis inducers targeting survival and migration in triple-negative breast cancer in-vitro","volume":"16","author":"Abd El Salam HA","year":"2026","unstructured":"Abd El Salam HA, Abu-Shahba N, Ibrahim Fouad G, Mahmoud M, Mostafa EA, Abozeid MAM, Abo-Salem HM, Azouz RAM. New indole-linked 1, 2, 4-triazole derivatives as dual FAK inhibitors and apoptosis inducers targeting survival and migration in triple-negative breast cancer in-vitro. Sci Rep. 2026;16(1):13134.","journal-title":"Sci Rep"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108677"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0954-x"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001651"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072346"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3RA07714D"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212272"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27010230"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116360"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112904"},{"issue":"5","key":"e_1_3_5_119_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1039\/D3MD00031A","article-title":"Antiproliferative activity and toxicity evaluation of 1, 2, 3-triazole and 4-methyl coumarin hybrids in the MCF7 breast cancer cell line","volume":"14","author":"Augsten LV","year":"2023","unstructured":"Augsten LV, G\u00f6ethel G, Gauer B, Feiffer Char\u00e3o M, von Poser G, Canto RFS, Arbo MD, Eifler-Lima VL, Garcia SC. Antiproliferative activity and toxicity evaluation of 1, 2, 3-triazole and 4-methyl coumarin hybrids in the MCF7 breast cancer cell line. RSC Med Chem. 2023;14(5):869\u2013879.","journal-title":"RSC Med Chem"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1890066"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116556"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030913"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2025.102182"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.02.018"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16748"},{"issue":"4","key":"e_1_3_5_126_1","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.7314\/APJCP.2014.15.4.1751","article-title":"Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients","volume":"15","author":"Ocal I","year":"2014","unstructured":"Ocal I, Avci A, Cakalagaoglu F, Can H. Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients. Asian Pac J Cancer Prev. 2014;15(4):1751\u20131755.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"e_1_3_5_127_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-025-02281-2","article-title":"3D tumor cultures for drug resistance and screening development in clinical applications","volume":"24","author":"Peng Z","year":"2025","unstructured":"Peng Z, Lv X, Sun H, Zhao L, Huang S. 3D tumor cultures for drug resistance and screening development in clinical applications. Mol Cancer. 2025;24(1):93.","journal-title":"Mol Cancer"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283271"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21334"},{"issue":"4","key":"e_1_3_5_130_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein\u2013ligand docking using GOLD","volume":"52","author":"Verdonk ML","year":"2003","unstructured":"Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein\u2013ligand docking using GOLD. Proteins Struct Funct Bioinforma. 2003;52(4):609\u2013623.","journal-title":"Proteins Struct Funct Bioinforma"},{"key":"e_1_3_5_131_1","doi-asserted-by":"crossref","first-page":"7062025","DOI":"10.25259\/AJC_706_2025","article-title":"Synthesis and molecular modeling of new triazole-oxadiazole and triazole-thiadiazole compounds as cytotoxic agents","volume":"19","author":"Almutairi HH","year":"2026","unstructured":"Almutairi HH, Alharbi A, Alanzy AL, Alomari K, Aljowni MA, Alessa A, Katouah HA, El-Metwaly N. Synthesis and molecular modeling of new triazole-oxadiazole and triazole-thiadiazole compounds as cytotoxic agents. Arab J Chem. 2026;19:7062025.","journal-title":"Arab J Chem"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110443"},{"issue":"1","key":"e_1_3_5_133_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13065-022-00812-2","article-title":"Fragment-based virtual screening discovers potential new Plasmodium PI4KIII\u03b2 ligands","volume":"16","author":"Ibezim A","year":"2022","unstructured":"Ibezim A, Madukaife MS, Osigwe SC, Engel N, Karuppasamy R, Ntie-Kang F. Fragment-based virtual screening discovers potential new Plasmodium PI4KIII\u03b2 ligands. BMC Chem. 2022;16(1):19.","journal-title":"BMC Chem"},{"key":"e_1_3_5_134_1","doi-asserted-by":"crossref","first-page":"1027890","DOI":"10.3389\/fphar.2022.1027890","article-title":"Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies","volume":"13","author":"Opo FADM","year":"2022","unstructured":"Opo FADM, Moulay M, Zari A, Alqaderi A, Alkarim S, Zari T, Bhuiyan MA, Mahmoud MM, Aljoud F, Suhail M, et al. Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. Front Pharmacol. 2022;13:1027890.","journal-title":"Front Pharmacol"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00487"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2014.08.013"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1177\/02611929211008196"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201700582"},{"issue":"8","key":"e_1_3_5_139_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00432-024-05903-2","article-title":"Advancements in triple-negative breast cancer sub-typing, diagnosis and treatment with assistance of artificial intelligence: a focused review","volume":"150","author":"Batool Z","year":"2024","unstructured":"Batool Z, Kamal MA, Shen B. Advancements in triple-negative breast cancer sub-typing, diagnosis and treatment with assistance of artificial intelligence: a focused review. J Cancer Res Clin Oncol. 2024;150(8):383.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"41","key":"e_1_3_5_140_1","doi-asserted-by":"crossref","first-page":"23766","DOI":"10.1039\/D0CP03596C","article-title":"Accurate predictions of aqueous solubility of drug molecules via the multilevel graph convolutional network (MGCN) and SchNet architectures","volume":"22","author":"Gao P","year":"2020","unstructured":"Gao P, Zhang J, Sun Y, Yu J. Accurate predictions of aqueous solubility of drug molecules via the multilevel graph convolutional network (MGCN) and SchNet architectures. Phys Chem Chem Phys. 2020;22(41):23766\u201323772.","journal-title":"Phys Chem Chem Phys"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c01496"},{"issue":"7","key":"e_1_3_5_142_1","doi-asserted-by":"crossref","first-page":"btae416","DOI":"10.1093\/bioinformatics\/btae416","article-title":"ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries","volume":"40","author":"Swanson K","year":"2024","unstructured":"Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, Shivnaraine RV, Zou J. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics. 2024;40(7):btae416.","journal-title":"Bioinformatics"},{"key":"e_1_3_5_143_1","doi-asserted-by":"crossref","first-page":"854965","DOI":"10.3389\/fphar.2022.854965","article-title":"Novel 1, 2, 3-triazole erlotinib derivatives as potent IDO1 inhibitors: design, drug-target interactions prediction, synthesis, biological evaluation, molecular docking and ADME properties studies","volume":"13","author":"Xu G-Q","year":"2022","unstructured":"Xu G-Q, Gong X-Q, Zhu Y-Y, Yao X-J, Peng L-Z, Sun G, Yang J-X, Mao L-F. Novel 1, 2, 3-triazole erlotinib derivatives as potent IDO1 inhibitors: design, drug-target interactions prediction, synthesis, biological evaluation, molecular docking and ADME properties studies. Front Pharmacol. 2022;13:854965.","journal-title":"Front Pharmacol"},{"issue":"1","key":"e_1_3_5_144_1","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1080\/14756366.2021.1954918","article-title":"New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study","volume":"36","author":"Maccallini C","year":"2021","unstructured":"Maccallini C, Gallorini M, Sisto F, Akdemir A, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Carradori S, Cataldi A, et al. New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study. J Enzyme Inhib Med Chem. 2021;36(1):1632\u20131645.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090335"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.26"},{"issue":"1","key":"e_1_3_5_147_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43042-024-00485-7","article-title":"Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context","volume":"25","author":"Saddam M","year":"2024","unstructured":"Saddam M, Paul SK, Habib MA, Fahim MA, Mimi A, Islam S, Paul B, Helal MMU. Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context. Egypt J Med Hum Genet. 2024;25(1):12.","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"e_1_3_5_148_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/toxres\/tfaa029","article-title":"Enhanced apoptogenesis and oncogene regulatory mechanism of troxerutin in triple negative breast cancer cells","volume":"9","author":"Saranya T","year":"2020","unstructured":"Saranya T, Kavithaa K, Paulpandi M, Ramya S, Preethi S, Balachandar V, Narayanasamy A. Enhanced apoptogenesis and oncogene regulatory mechanism of troxerutin in triple negative breast cancer cells. Toxicol Res (Camb). 2020;9(3):230\u2013238.","journal-title":"Toxicol Res (Camb)"},{"issue":"1","key":"e_1_3_5_149_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12967-025-06077-2","article-title":"A review of the pathogenesis of mitochondria in breast cancer and progress of targeting mitochondria for breast cancer treatment","volume":"23","author":"Huang A","year":"2025","unstructured":"Huang A, Xue H, Xie T, Xiang L, Chen Z, Ma A, Yan H, Yuan J. A review of the pathogenesis of mitochondria in breast cancer and progress of targeting mitochondria for breast cancer treatment. J Transl Med. 2025;23(1):70.","journal-title":"J Transl Med"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c03325"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040819"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135181"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041320"},{"issue":"1","key":"e_1_3_5_154_1","doi-asserted-by":"crossref","first-page":"e2100158","DOI":"10.1002\/ardp.202100158","article-title":"1, 2, 3-Triazole hybrids as anticancer agents: a review","volume":"355","author":"Alam MM.","year":"2022","unstructured":"Alam MM. 1, 2, 3-Triazole hybrids as anticancer agents: a review. Arch Pharm (Weinheim). 2022;355(1):e2100158.","journal-title":"Arch Pharm (Weinheim)"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161282005140214165212"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.03.023"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.050492"},{"key":"e_1_3_5_158_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1039\/D2MD00356B","article-title":"Therapeutic significance of molecular hybrids for breast cancer research and treatment","volume":"14","author":"Ahmad I.","year":"2023","unstructured":"Ahmad I. Therapeutic significance of molecular hybrids for breast cancer research and treatment. RSC Med Chem. 2023;14:218\u2013238.","journal-title":"RSC Med Chem"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.61"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01985"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02476-1"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2022.2129613"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1039\/D4MD00522H"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43088-024-00566-x"},{"key":"e_1_3_5_165_1","first-page":"040","article-title":"Overcoming multifaceted challenges in cancer treatment: targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy","volume":"15","author":"Ansari AM","year":"2025","unstructured":"Ansari AM, Sharma NK, Tripathi K, Bhardwaj G, Chauhan R, Tonk RK, Shahwan M, Tuli HS, Chauhan A. Overcoming multifaceted challenges in cancer treatment: targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy. J Appl Pharm Sci. 2025;15:040\u2013063.","journal-title":"J Appl Pharm Sci"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00790"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111961"},{"issue":"1","key":"e_1_3_5_168_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12645-025-00321-6","article-title":"In vitro methodologies to evaluate nanocarriers for cancer treatment: where are we?","volume":"16","author":"Salata GC","year":"2025","unstructured":"Salata GC, Hirokawa CM, de Melo GB, Malag\u00f3 ID, Nunes JR, Passos JS, Dar\u00e9 RG, Lopes LB. In vitro methodologies to evaluate nanocarriers for cancer treatment: where are we? Cancer Nano. 2025;16(1):21.","journal-title":"Cancer Nano"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2024.134122"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213455"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2732821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14756366.2026.2732821","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2732821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:09:22Z","timestamp":1790593762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2732821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":169,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2732821"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2732821","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2732821"}}